검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | MDX-010 (CTLA-4) |
Overview Company | Bristol-Myers Squibb |
Overview Modality | ANTIBODY |
Overview Target | Melanoma |
Overview Indication | Melanoma |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
MoA Mechanism | targeting immune checkpoints - regulatory pathway |
MoA Biomarker | PD-1/PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), high |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Severe renal and pancreatic toxicities associated with ipilimumab and nivolumab combination therapy in non-small cell lung cancer: a pharmacovigilance analysis of the FDA adverse event reporting system.. Ipilimumab plus nivolumab (Ipi+Nivo) has become a standard therapy for advanced non-small cell lung cancer (NSCLC), yet severe organ-specific toxicities remain inadequately characterized. This stu… |
Toxicology CRS | Reported |
Clinical Primary efficacy | ORR 23.1% |
Clinical ORR | 23.1% |
Clinical Result source | ClinicalTrials.gov NCT03459222 |
Clinical Data Tier / Score | A · 39 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 6일 (8일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | MDX-010 (CTLA-4) |
Overview Company | Bristol-Myers Squibb |
Overview Modality | ANTIBODY |
Overview Target | Melanoma |
Overview Indication | Melanoma |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
MoA Mechanism | targeting immune checkpoints - regulatory pathway |
MoA Biomarker | PD-1/PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), high |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Severe renal and pancreatic toxicities associated with ipilimumab and nivolumab combination therapy in non-small cell lung cancer: a pharmacovigilance analysis of the FDA adverse event reporting system.. Ipilimumab plus nivolumab (Ipi+Nivo) has become a standard therapy for advanced non-small cell lung cancer (NSCLC), yet severe organ-specific toxicities remain inadequately characterized. This stu… |
Toxicology CRS | Reported |
Clinical Primary efficacy | ORR 23.1% |
Clinical ORR | 23.1% |
Clinical Result source | ClinicalTrials.gov NCT03459222 |
Clinical Data Tier / Score | A · 39 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 6일 (8일 전) |
추천 비교
추천 비교